Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 7, 2026, 4:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Type 1 Diabetes Clear all
Terminated Phase 1Phase 2 Interventional

Neoadjuvant Durvalumab and Tremelimumab Plus Radiation for High Risk Soft-Tissue Sarcoma

NCT03116529
View directory record Official record
Conditions
Soft Tissue Sarcoma
Interventions
Combination Radiation, Immunotherapy, Surgery
Combination Product
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
3
States / cities
Tucson, Arizona • Baltimore, Maryland • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 3, 2024 · Synced Jun 7, 2026, 4:27 AM EDT
Completed Not applicable Interventional Results available

TRIGR - Primary Prevention Study for Type 1 Diabetes in Children at Risk

NCT00179777
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Hydrolysed infant formula, Nonhydrolysed infant formula
Dietary Supplement
Lead sponsor
University of Helsinki
Other
Eligibility
Up to 7 Days
Enrollment
5,156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2017
U.S. locations
2
States / cities
Tampa, Florida • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 29, 2021 · Synced Jun 7, 2026, 4:27 AM EDT
Completed Phase 2 Interventional Results available

A Euglycemic Insulin Clamp Study in Type 1 Diabetic Patients With Oral Insulin (ORAMED)

NCT02535715
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
ORMD-0801 capsules- 2x8mg, ORMD-0801 capsules- 3x8mg, ORMD-0801 capsules- 1x16mg
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 70 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 20, 2019 · Synced Jun 7, 2026, 4:27 AM EDT
Completed Phase 1 Interventional Results available

4-Week, Multiple-dose, Dose-escalating Study In Patients With Type 2 Diabetes

NCT03538743
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Placebo, PF-06882961
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
4
States / cities
Anaheim, California • South Miami, Florida • Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 30, 2020 · Synced Jun 7, 2026, 4:27 AM EDT
Recruiting Not applicable Interventional

To Study the Efficacy and Safety of Medtronic 780G Insulin Pump in People With Gastroparesis and Type 1 Diabetes.

NCT07287943
View directory record Official record
Conditions
Type 1 Diabetes, Gastroparesis Due to Diabetes Mellitus Type I
Interventions
Medtronic 780G AID
Device
Lead sponsor
Viral N. Shah
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Jun 7, 2026, 4:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Tissue-Specific Metabolic Reprogramming in Diabetic Complications

NCT01823406
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Euglycemic clamp (normal blood sugar clamp) for 4 hours, hyperglycemic clamp (elevated blood sugar to 300) for 4 hours
Procedure
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 27, 2018 · Synced Jun 7, 2026, 4:27 AM EDT
Completed Not applicable Interventional Results available

Evaluation of Accuracy of Continuous Glucose Monitoring (CGM) in Patients With End Stage Renal Disease (ESRD) on Intermittent Hemodialysis (iHD).

NCT04094064
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions
Continuous Glucose Monitor
Device
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 20, 2022 · Synced Jun 7, 2026, 4:27 AM EDT
Completed Not applicable Interventional Results available

Adaptation of Insulin Delivery Settings to Improve Clinical Outcomes With AID Use

NCT05204134
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Automated Insulin Delivery Settings Initialization and Adaptation Algorithm
Device
Lead sponsor
Tandem Diabetes Care, Inc.
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 4, 2024 · Synced Jun 7, 2026, 4:27 AM EDT
No Longer Available No phase listed Expanded access

Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder

NCT01798914
View directory record Official record
Conditions
Type 1 Diabetes, Type 2 Diabetes
Interventions
Technosphere Insulin Inhalation Powder
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
14
States / cities
Montgomery, Alabama • Miami, Florida • Orland Park, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2016 · Synced Jun 7, 2026, 4:27 AM EDT
Completed Phase 1 Interventional

Islet After Kidney Transplantation (IAK) in Patients With Type 1 Diabetes

NCT00708604
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Islet Transplantation, Islet cell transplantation
Procedure · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced Jun 7, 2026, 4:27 AM EDT
Completed No phase listed Observational

Sleep, Coping and Executive Functioning in Youth With Type 1 Diabetes

NCT02908555
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
No intervention
Other
Lead sponsor
Yale University
Other
Eligibility
10 Years to 16 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 1, 2018 · Synced Jun 7, 2026, 4:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Assessing an Insulin Pump-controlling Algorithm to Minimize Hypo and Hyper in Type 1 During CRC Setting

NCT01638299
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Hypo-Hyper Minimizer (HHM) System
Device
Lead sponsor
Animas Corporation
Industry
Eligibility
21 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
2
States / cities
Santa Barbara, California • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 20, 2012 · Synced Jun 7, 2026, 4:27 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Adults With Type 1 Diabetes

NCT02500706
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1
Interventions
Faster-acting insulin aspart, insulin aspart, insulin degludec
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
1,108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
57
States / cities
Tucson, Arizona • Concord, California • Encino, California + 49 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2019 · Synced Jun 7, 2026, 4:27 AM EDT
Not listed Phase 1 Interventional

PK/PD Study of Intranasal Insulin in Type I Diabetes

NCT01201278
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Insulin, Insulin LISPRO
Drug
Lead sponsor
Hompesch, Marcus, M.D.
Individual
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jun 16, 2011 · Synced Jun 7, 2026, 4:27 AM EDT
Completed Not applicable Interventional Results available

Longevity of Multi-Slitted Catheter With Lantern Technology

NCT03819634
View directory record Official record
Conditions
Insulin Dependent Diabetes Mellitus 1
Interventions
Inset II with Lantern Technology
Device
Lead sponsor
Stanford University
Other
Eligibility
22 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated May 24, 2021 · Synced Jun 7, 2026, 4:27 AM EDT
Terminated Not applicable Interventional

Native American Diabetes Project

NCT05088616
View directory record Official record
Conditions
Diabetes, Diabete Type 2, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetes Type 1, Diabetes Mellitus
Interventions
Virtual Diabetes Wellness Classes and Medically Tailored Meals
Behavioral
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 21, 2025 · Synced Jun 7, 2026, 4:27 AM EDT
Completed Phase 3 Interventional

Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes

NCT00044395
View directory record Official record
Conditions
Diabetic Neuropathies, Diabetes Mellitus, Insulin-Dependent, Diabetes Mellitus, Non-Insulin-Dependent
Interventions
Ruboxistaurin mesylate
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
19
States / cities
Mesa, Arizona • Irvine, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2007 · Synced Jun 7, 2026, 4:27 AM EDT
Completed Not applicable Interventional

Reducing Distress And Improving Glycemic Control In Adults With Type 1 Diabetes

NCT02175732
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
'KnowIt', 'OnTrack'
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
19 Years and older
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 24, 2019 · Synced Jun 7, 2026, 4:27 AM EDT
Completed No phase listed Observational Results available

An Observational Study Evaluating SYMLIN® (Pramlintide Acetate) Injection Use in Insulin Using Patients With Type 2 and Type 1 Diabetes

NCT00229658
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Interventions
pramlintide acetate
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
1,297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
107
States / cities
Birmingham, Alabama • Montgomery, Alabama • Tucson, Arizona + 104 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2015 · Synced Jun 7, 2026, 4:27 AM EDT
Completed No phase listed Observational

Clinical Evaluation of BD NEXT Pen Needle

NCT01852136
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
Interventions
BD NEXT 31G x 5 mm pen needle, BD NEXT 31G x 8mm pen needle, BD NEXT 32G x 4mm pen needle
Device
Lead sponsor
Becton, Dickinson and Company
Industry
Eligibility
35 Years to 80 Years
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
4
States / cities
Toms River, New Jersey • Asheville, North Carolina • Kingsport, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2017 · Synced Jun 7, 2026, 4:27 AM EDT
Completed Phase 1 Interventional Results available

T1DM Immunotherapy Using CD4+CD127lo/-CD25+ Polyclonal Tregs

NCT01210664
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Ex vivo Expanded Human Autologous Polyclonal Regulatory T Cells
Biological
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 45 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
2
States / cities
San Francisco, California • New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 10, 2018 · Synced Jun 7, 2026, 4:27 AM EDT
Completed Phase 1 Interventional Results available

A Pilot Study of the Therapeutic Potential of Stem Cell Educator Therapy in Type 1 Diabetes

NCT02624804
View directory record Official record
Conditions
Diabetes Mellitus Type 1
Interventions
Stem Cell Educator Therapy
Biological
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Jun 7, 2026, 4:27 AM EDT
Terminated Phase 3 Interventional

GALLEX 1 - Long Term Extension Study in Patients With Type 2 Diabetes

NCT00252876
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
tesaglitazar
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
58
States / cities
Birmingham, Alabama • Columbiana, Alabama • Mobile, Alabama + 55 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2008 · Synced Jun 7, 2026, 4:27 AM EDT
Completed Phase 1 Interventional Results available

Multiple Dose Study Of PF-05231023 In Adult Subjects Who Have Poor Lipid Control With And Without Type 2 Diabetes Mellitus

NCT01673178
View directory record Official record
Conditions
Diabetes Melliuts, Type 2
Interventions
Placebo, 25 mg PF-05231023, 50 mg PF-05231023, 100 mg PF-05231023, 150 mg PF-05231023
Other · Drug
Lead sponsor
Pfizer
Industry
Eligibility
30 Years to 70 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
17
States / cities
Anaheim, California • Chula Vista, California • Walnut Creek, California + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2015 · Synced Jun 7, 2026, 4:27 AM EDT